Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000104.xml
Download PDF
Zentralbl Chir 2014; 139(2): 175-183
DOI: 10.1055/s-0033-1350669
DOI: 10.1055/s-0033-1350669
Übersicht
Hepatozelluläres Karzinom – Aktuelles zu Screening, Surveillance und Therapiestrategien (aktualisierte EASL-EORTC-Empfehlungen)
Hepatocellular Carcinoma – Current Aspects of Screening, Surveillance and Therapeutic Strategies (Revised EASL-EORTC Recommendations)Further Information
Publication History
Publication Date:
16 October 2013 (online)
Zusammenfassung
Das hepatozelluläre Karzinom (HCC) gehört mit 523 000 neuen Fällen pro Jahr zu den häufigsten Krebsentitäten weltweit. In den letzten Jahren haben sich sowohl hinsichtlich der Diagnostik als auch in Bezug auf die therapeutischen Optionen deutliche Verbesserungen ergeben. Die Überwachung von Risikopatienten führt zu einer frühzeitigeren Diagnose kleiner HCCs. Nach wie vor ist eine frühe Diagnose die beste Voraussetzung für ein kuratives Therapiekonzept. Die vorliegende Übersichtsarbeit fasst die aktuellen Leitlinien der European Association for the Study of the Liver (EASL) und der European Organisation for Research and Treatment of Cancer (EORTC) unter besondere Berücksichtigung des Screenings und der Surveillance von Risikogruppen für das HCC zusammen.
Abstract
With an incidence of 523 000 new cases a year hepatocellular carcinomas (HCCs) belong to the most frequent cancer entities worldwide. Diagnostic and therapeutic procederes have been improved during the last years. Surveillance of patients with high risk factors leads to an early diagnosis. Up to now the detection of early HCCs represents the best prerequisite for any curative therapy. The present synopsis summarises the current guidelines of the European Association for the Study of the Liver (EASL) and the European Organisation for Research and Treatment of Cancer (EORTC) with a special focus on screening and surveillance of risk groups.
-
Literatur
- 1 European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943
- 2 National Cancer Institute. PDQ_ levels of evidence for adult and pediatric cancer treatment studies. Bethesda, MD: National Cancer Institute. Date last modified 06/January/2013. Im Internet:. http://cancer.gov/cancertopics/pdq/levelsevidence-adult-treatment/healthprofessional/ Stand: 26.08.2010
- 3 Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J Clin
2005; 55: 74-108
MissingFormLabel
- 4 International Agency for Research on Cancer (IARC). CancerMondial. Im Internet:. http://www-dep.iarc.fr/ Stand: 11.01.2013
- 5 El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-750
- 6 Tanaka H, Imai Y, Hiramatsu N et al. Declining incidence of hepatocellular carcinoma in Osaka, Japan from 1990 to 2003. Ann Intern Med 2008; 148: 820-826
- 7 Bosetti C, Boffetta P, Lucchini F et al. Trends in mortality from hepatocellular carcinoma in Europe, 1980–2004. Hepatology 2008; 48: 137-145
- 8 Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96
- 9 Erhardt A, Zhu E, Blondin D et al. [Increasing number and improved survival of patients with hepatocellular carcinoma from 1988 to 2007: data of a German university clinic]. Z Gastroenterol 2011; 49: 720-727
- 10 Chang MH, You SL, Chen CJ et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009; 101: 1348-1355
- 11 Sangiovanni A, Prati GM, Fasani P et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 2006; 43: 1303-1310
- 12 Ioannou G, Splan M, Weiss N et al. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2007; 5: 938-945
- 13 Masuzaki R, Tateishi R, Yoshida H et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology 2009; 49: 1954-1961
- 14 Jung KS, Kim SU, Ahn SH et al. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology 2011; 53: 885-894
- 15 Lok AS, Seeff LB, Morgan TR et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009; 136: 138-148
- 16 Yang HI, Lu SN, Liaw YF et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-174
- 17 Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73
- 18 Iloeje UH, Yang HI, Su J et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-686
- 19 Raimondi S, Bruno S, Mondelli MU et al. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J Hepatol 2009; 50: 1142-1154
- 20 Hsu IC, Metcalf RA, Sun T et al. Mutational hotspot in the p 53 gene in human hepatocellular carcinomas. Nature 1991; 350: 427-428
- 21 Deugnier YM, Guyader D, Crantock L et al. Primary liver cancer in genetic hemochromatosis: a clinical, pathological, and pathogenetic study of 54 cases. Gastroenterology 1993; 104: 228-234
- 22 Perlmutter DH. Pathogenesis of chronic liver injury and hepatocellular carcinoma in alpha-1-antitrypsin deficiency. Pediatr Res 2006; 60: 233-238
- 23 Polio J, Enriquez RE, Chow A et al. Hepatocellular carcinoma in Wilsonʼs disease. Case report and review of the literature. J Clin Gastroenterol 1989; 11: 220-224
- 24 Marrero JA, Fontana RJ, Fu S et al. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol 2005; 42: 218-224
- 25 Roeb E. [NASH (Non-Alcoholic Steatohepatitis): Fatty Liver or Fatal Liver Disease?]. Zentralbl Chir 2012; Mar 22. [Epub ahead of print]
- 26 Trichopoulos D, Bamia C, Lagiou P et al. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case–control study. J Natl Cancer Inst 2011; 103: 1686-1695
- 27 Marcellin P, Pequignot F, Delarocque-Astagneau E et al. Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. J Hepatol 2008; 48: 200-207
- 28 Tanabe KK, Lemoine A, Finkelstein DM et al. Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA 2008; 299: 53-60
- 29 Abu Dayyeh BK, Yang M, Fuchs BC et al. A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology 2011; 141: 141-149
- 30 Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med 1996; 101: 422-434
- 31 Fattovich G, Stroffolini T, Zagni I et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127 (Suppl. 01) S35-S50
- 32 Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022
- 33 Di Bisceglie AM. Issues in screening and surveillance for hepatocellular carcinoma. Gastroenterology 2004; 127 (Suppl. 01) S104-S107
- 34 Martínez SM, Crespo G, Navasa M et al. Noninvasive assessment of liver fibrosis. Hepatology 2011; 53: 325-335
- 35 Craxì A, Cammà C. Prevention of hepatocellular carcinoma. Clin Liver Dis 2005; 9: 329-346
- 36 Bruno S, Stroffolini T, Colombo M et al. Italian Association of the Study of the Liver Disease (AISF). Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 579-587
- 37 Sung JJ, Tsoi KK, Wong VW et al. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008; 28: 1067-1077
- 38 Lampertico P, Viganò M, Manenti E et al. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007; 133: 1445-1451
- 39 Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. J Hepatol 2003; 39: 1076-1084
- 40 Kim CK, Lim JH, Lee WJ. Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver: accuracy of ultrasonography in transplant patients. J Ultrasound Med 2001; 20: 99-104
- 41 Barreiros AP, Piscaglia F, Dietrich CF. Contrast enhanced ultrasound for the diagnosis of hepatocellular carcinoma (HCC): comments on AASLD guidelines. J Hepatol 2012; 57: 930-932
- 42 Singal A, Volk ML, Waljee A et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009; 30: 37-47
- 43 Sato T, Tateishi R, Yoshida H et al. Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C. Hepatol Int 2009; 3: 544-550
- 44 Bolondi L, Gaiani S, Celli N et al. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology 2005; 42: 27-34
- 45 Pateron D, Ganne N, Trinchet JC et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 1994; 20: 65-71
- 46 Santi V, Trevisani F, Gramenzi A et al. Italian Liver Cancer (ITA.LI.CA) Group. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol 2010; 53: 291-297
- 47 Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48 (Suppl. 01) S20-S37
- 48 International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009; 49: 658-664
- 49 Neeff H, Makowiec F, Harder J et al. [Hepatic resection for hepatocellular carcinoma–results and analysis of the current literature]. Zentralbl Chir 2009; 134: 127-135
- 50 Mazzaferro V, Battiston C, Perrone S et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 2004; 240: 900-909
- 51 Lu DS, Yu NC, Raman SS et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 2005; 41: 1130-1137
- 52 Majno PE, Adam R, Bismuth H et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997; 226: 688-701
- 53 Czymek R, Gebhard M, Lubienski A et al. Intrahepatische Ablation: Radiofrequenzablation versus Elektrochemische Lyse. Zentralbl Chir 2011; 136: 379-385
- 54 Arguedas MR, Chen VK, Eloubeidi MA et al. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol 2003; 98: 679-690
- 55 Lin OS, Keeffe EB, Sanders GD et al. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther 2004; 19: 1159-1172
- 56 Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 417-422
- 57 Trevisani F, De Notariis S, Rapaccini G et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002; 97: 734-744
- 58 Bolondi L, Sofia S, Siringo S et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001; 48: 251-259